Facing the Looming End of Fee-for-Service, Clinical Laboratories and Anatomic Pathology Groups Look for New Business Models

Failing finances at technical pathology laboratories may be the most immediate concern for many pathology group practices Many clinical laboratories and anatomic pathology groups now recognize the new reality of the American healthcare system: less reimbursement for laboratory testing. On one hand, the fee-for-service prices for lab tests paid by government and private payers have been aggressively slashed. On the other hand, all payers have become stubbornly resistant to issuing coverage...

Siemens Health CEO Erich Reinhardt Discusses Integration of Imaging and Lab Testing

On Wednesday of last week, Prof. Dr. Erich R. Reinhardt, President and CEO of Siemens Medical Solutions (NYSE: SI), traveled from Germany to the United States to deliver an address on how Siemens expects to integrate in vivo (imaging) diagnostics, in vitro diagnostics (IVD), and informatics to create new value streams in healthcare. This is a topic of high interest within the laboratory community, ever since Siemens spent billions to buy a major presence in the lab testing marketplace last...
;